Evidence map›Paper›PMID 36950277›Full record

ArticleScience and technology of advanced materials2023

Block catiomers with flanking hydrolyzable tyrosinate groups enhance

Wenqian Yang, Takuya Miyazaki, Yasuhiro Nakagawa, Eger Boonstra, Keita Masuda, Yuki Nakashima, Pengwen Chen, Lucas Mixich, Kevin Barthelmes, Akira Matsumoto and 3 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science and technology of advanced materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Recent trends in the delivery of RNA drugs: Beyond the liver, more than vaccine.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2024
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Wenqian YangDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9349-2240
Takuya MiyazakiKanagawa Institute of Industrial Science and Technology, Ebina, Japan.
Yasuhiro NakagawaDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-2152-3519
Eger BoonstraDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5386-7711
Keita MasudaDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Yuki NakashimaDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Pengwen ChenDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Lucas MixichDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Kevin BarthelmesKanagawa Institute of Industrial Science and Technology, Ebina, Japan.
Akira MatsumotoInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7568-8677
Peng MiDepartment of Radiology, Center for Medical Imaging, and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Satoshi UchidaGraduate School of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Horacio CabralDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4030-2631
The University of Tokyo · JPKanagawa Industrial Technology Center · JPSichuan University · CNKyoto Prefectural University of Medicine · JPTokyo Institute of Technology · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Messenger RNA (mRNA) therapeutics have recently demonstrated high clinical potential with the accelerated approval of SARS-CoV-2 vaccines. To fulfill the promise of unprecedented mRNA-based treatments, the development of safe and efficient carriers is still necessary to achieve effective delivery of mRNA. Herein, we prepared mRNA-loaded nanocarriers for enhanced

Indexed as

biocompatibleMessenger RNAnanomedicinepoly(ethylene glycol)-poly(glycerol)polymeric micellesπ–π interaction

Identifiers

PMID36950277
PMCPMC10026751
OpenAlexW4317743382

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read72
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.